Physician profile
Paul M Chlpka, JR.
NPI 1689659120
$2,818.96
in general payments reported to CMS, 2019-2025
23 companies · $292 in 2025
The $292 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $316 · 2021: $532 · 2022: $398 · 2023: $420 · 2024: $366 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $541.12 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Pfizer INC. | $380.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $305.47 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $296.26 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $271.01 | 2019-2025 | |
| Tris Pharma INC | $184.37 | 2019-2021 | |
| Kaleo, INC. | $182.13 | 2019-2023 | Auvi-Q |
| Seqirus USA INC | $146.81 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $70.99 | 2021-2022 | |
| Sobi, INC | $70.91 | 2019-2021 | |
| Neurelis, INC. | $59.76 | 2022-2023 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $55.80 | 2020-2022 | |
| Cognoa, INC. | $47.73 | 2021-2022 | |
| Genentech USA, INC. | $36.43 | 2020-2021 | |
| Verrica Pharmaceuticals INC. | $32.03 | 2023-2024 | Ycanth |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.15 | 2025 | |
| Phadia US INC. | $18.13 | 2024 | Immunocap |
| Collegium Pharmaceutical, INC. | $17.61 | 2025 | Jornay Pm |
| Amneal Pharmaceuticals LLC | $16.92 | 2019 | |
| Shire North American Group INC | $15.74 | 2019 | |
| Mission Pharmacal Company | $15.72 | 2019 | |
| Corium, LLC | $14.37 | 2022 | |
| Cranial Technologies, INC | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chlpka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.